Glucose-lowering therapy after myocardial infarction: more questions than answers
- PMID: 18199566
- DOI: 10.1093/eurheartj/ehm595
Glucose-lowering therapy after myocardial infarction: more questions than answers
Abstract
This editorial refers to The impact of glucose-lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial by L.G. Mellbin et al., on page 166 and Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart by M. Alselmino et al., on page 177
Comment on
-
Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart.Eur Heart J. 2008 Jan;29(2):177-84. doi: 10.1093/eurheartj/ehm519. Epub 2007 Dec 21. Eur Heart J. 2008. PMID: 18156611
-
The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.Eur Heart J. 2008 Jan;29(2):166-76. doi: 10.1093/eurheartj/ehm518. Epub 2007 Dec 21. Eur Heart J. 2008. PMID: 18156614 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
